NMPA has approved Xi'an Jansen-type ® (REMICADE®) for the treatment of adult patients with ulcerative colitis

recently, the U.SPharmaceutical(http://giant Johnson and Johnson (http:// in ChinaPharmaceutical(http://Company(http://Xi'an Yangsen Pharmaceutical Co., Ltdannounced that China's NationalPharmaceutical(http://Supervision Authority (NMPA) has approved theof® the class of grams (HTTP://WWW.CHEMDRUG.COM/) ®, injection inthe invictliated patients with adverse effects of traditional treatment, intolerantclass ® can help alleviate symptoms and signs of the disease, induce and maintain clinical remission and mucous membrane healing, and reduce or stop using saccharine in patientson ®
-type ® is the first biological agent in China to be approved for three different areas of gastroenterology, rheumatism and dermatology since its since its listing in 2006, the ® has been approved for use in adult synod patients with Crohn's disease, moderate to severe active Crohn's disease, patients with moderate lycincoid croencephaliand, patients with active hyperthyroidism, and other systems that require systematic treatment and are not effective, contraindication or intolerance to cyclosporine, methotrexate or phototherapy 　　UC is the drug's seventh indication approved in China To date, the ® has been approved in more than 100 countries around the world, and is widely used in more than 3 million patients worldwide